U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend

The article highlights Eli Lilly (LLY) and Intuitive Surgical (ISRG) as beneficiaries of healthcare spending growth (sector cited at $5.7T, +7.3% vs. 2024) and long-run tailwinds like GLP-1/weight-loss demand and robotic-assisted surgery penetration. For Lilly, the core argument is sustained momentum from GLP-1 products (e.g., Mounjaro, Zepbound/“Foundayo”) plus pipeline expansion (e.g., phase 3 retatrutide) and increased AI use to improve drug development economics. For Intuitive Surgical, it emphasizes recurring instrument revenue tied to procedure volumes, ongoing da Vinci 5 adoption (launched 2024), and the ability to offset “steep tariffs” via pricing power, despite some competitive/tariff headwinds.

Analysis

This is mostly a quality-screen reaffirmation, not a fresh catalyst. The real market mechanism is that capital is still concentrating in a narrow set of healthcare franchises with pricing power and durable demand, which tends to widen the valuation gap versus the rest of the sector. For LLY, the upside is less about current sales and more about how long the obesity franchise can compound before payer pushback turns it into a budget-politics issue.

The second-order winner is likely LLY’s share in the category, not just the category itself: every incremental proof point raises the hurdle for NVO and makes switching harder for physicians and patients. The main near-term risk is not demand failure but normalization risk — if weekly script growth or net price realization slows, the stock can de-rate quickly because expectations are already for multi-year dominance. Over 6-18 months, the key falsifier is any sign that the pipeline is only defending share instead of expanding the treated population.

ISRG is a different story: a high-quality annuity with less fundamental upside from the article than the market may imply. Disposable instrument revenue and installed-base leverage should keep compounding, but the multiple is sensitive to procedure growth and to whether hospitals absorb tariff/pass-through pressure without slowing capital spending. The contrarian angle is that robotics competition matters less than people think unless a rival can break the ecosystem lock-in; the real risk is that premium valuation compresses before competition does.

Key Decisions for Investors

• Long LLY vs short NVO over 3-6 months: express relative share-gain momentum in GLP-1s rather than broad healthcare beta; fade only if NVO US prescription growth re-accelerates or LLY guidance underwhelms.
• Use pullbacks to build a tactical long in LLY, but only on 5-8% drawdowns or after a weak tape; risk/reward is best if the market is temporarily discounting payer scrutiny rather than a true demand slowdown.
• Keep ISRG on a watchlist rather than chasing it here; wait for confirmation that tariff mitigation and procedure growth are offsetting capex softness before adding risk.
• If ISRG prints another quarter with procedure growth staying above high-single digits and pricing actions holding, consider a defined-risk bullish structure rather than outright stock due to valuation sensitivity.
• Falsifiers to monitor: LLY net pricing or weekly script deceleration, ISRG procedure growth falling below low-double digits, or any guidance revision tied to reimbursement/tariffs.